Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs

被引：0
|
作者：
Michael Fiegl
Lars H. Lindner
Matthias Juergens
Hansjoerg Eibl
Wolfgang Hiddemann
Jan Braess
机构：
[1] Ludwig-Maximilians University,Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern
[2] GSF-National Research Center for Environment and Health,Institute of Molecular Immunology
[3] GSF-National Research Center for Environment and Health,Clinical Cooperative Group Acute Myeloid Leukemia
[4] Max Planck Institute for Biophysical Chemistry,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2008年 / 62卷
关键词：
AML; Alkylphosphocholine; Cytarabine; Cytotoxicity; Interaction analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：321 / 329
页数：8
相关论文
共 50 条
  • [1] Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs
    Fiegl, Michael
    Lindner, Lars H.
    Juergens, Matthias
    Eibl, Hansjoerg
    Hiddemann, Wolfgang
    Braess, Jan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (02) : 321 - 329
  • [2] Antileukemic activity of rapamycin in acute myeloid leukemia
    Récher, C
    Beyne-Rauzy, O
    Demur, C
    Chicanne, G
    Dos Santos, C
    Mansat-De Mas, V
    Benzaquen, D
    Laurent, G
    Huguet, F
    Payrastre, B
    BLOOD, 2005, 105 (06) : 2527 - 2534
  • [3] ERUFOSINE, A NOVEL ALKYLPHOSPHOCHOLINE, IN CHRONIC LYMPHOCYTIC LEUKEMIA: IN VITRO COMPARISON WITH BENDAMUSTINE AND FLUDARABINE
    Konstantinov, S.
    Josifov, D.
    Alaikov, T.
    Shivarov, V.
    Stoyanov, N.
    Guenova, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 599 - 599
  • [4] HDAC6 as a target for antileukemic drugs in acute myeloid leukemia
    Hackanson, Bjoern
    Rimmele, Leander
    Benkisser, Marco
    Abdelkarim, Mahmoud
    Fliegauf, Manfred
    Jung, Manfred
    Luebbert, Michael
    LEUKEMIA RESEARCH, 2012, 36 (08) : 1055 - 1062
  • [5] Azelaic Acid Exerts Antileukemic Activity in Acute Myeloid Leukemia
    Pan, Yunbao
    Liu, Dong
    Wei, Yongchang
    Su, Dan
    Lu, Chenyang
    Hu, Yanchao
    Zhou, Fuling
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [6] Novel and Emerging Drugs for Acute Myeloid Leukemia: Pharmacology and Therapeutic Activity
    Robak, T.
    Szmigielska-Kaplon, A.
    Pluta, A.
    Grzybowska-Izydorczyk, O.
    Wolska, A.
    Czemerska, M.
    Wierzbowska, A.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (05) : 638 - 666
  • [7] Novel and Emerging Drugs for Acute Myeloid Leukemia
    Stein, E. M.
    Tallman, M. S.
    CURRENT CANCER DRUG TARGETS, 2012, 12 (05) : 522 - 530
  • [8] Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia
    Meunier, Godelieve
    Birsen, Rudy
    Cazelles, Clarisse
    Belhadj, Maya
    Cantero-Aguilar, Lilia
    Kosmider, Olivier
    Fontenay, Michaela
    Azar, Nabih
    Mayeux, Patrick
    Chapuis, Nicolas
    Tamburini, Jerome
    Bouscary, Didier
    ONCOGENESIS, 2020, 9 (10)
  • [9] Antileukemic activity of 2-deoxy-d-glucose in acute myeloid leukemia
    Larrue, Clement
    Manenti, Stephane
    Recher, Christian
    CANCER RESEARCH, 2014, 74 (19)
  • [10] Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia
    Godelieve Meunier
    Rudy Birsen
    Clarisse Cazelles
    Maya Belhadj
    Lilia Cantero-Aguilar
    Olivier Kosmider
    Michaela Fontenay
    Nabih Azar
    Patrick Mayeux
    Nicolas Chapuis
    Jerôme Tamburini
    Didier Bouscary
    Oncogenesis, 9
12345